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The mission of the Initiative is to create a win–win con-
cept where we join forces to clean up the afﬁnity reagent
market.
http://dx.doi.org/10.1016/j.euprot.2015.07.004
Improving productivity and quality in
Biobanking: The need for synergy between
industry, academia, and the public sector
Åsa Wheelock
Karolinska Institutet, Stockholm, Sweden
The mission of the recently launched EuPA Biobank Ini-
tiative (www.eupa-biobank.eu) is to provide a forum and a
knowledge platform to the EuPA community regarding best
biobanking practices for a range of different applications and
situations, including both classical biobanking issues such
as standardized guidelines for successful in-house biobank-
ing or evaluation of sample stability and quality, as well as
more recently identiﬁed issues such as under-utilization of
biobank materials. These goals will be attained primarily by
acting as a link between the extensive experiences collected
by the EuPA community and the European and international
biobanking organizations, and ideally also to patient advocacy
groups and the biotech and pharma industry. The potential
beneﬁts of providing a forum and easy access to this type of
information to EuPA and the scientiﬁc community at large are
manifold, including improved quality of future sample collec-
tions and biobanks, improvedquality of the research produced
from these samples collections, as well as increased output
and productivity from existing biobanks. We are convinced
that, in order to reach extraordinary results, academia, indus-
try, and the public sector need to join forces. Through joint
efforts, we can contribute to moving biomedical proteomics
research beyond basic ﬁndings into clinical practice.
http://dx.doi.org/10.1016/j.euprot.2015.07.005
Independent validation initiative
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The reproducibility of scientiﬁc results is increasingly in the
spotlight within the scientiﬁc community and even beyond.
As one of the keystone reagents for proteomics research, anti-
bodies are of particular interest in this context. Commercially
available antibodies that do not perform according to expecta-
tion are putting a considerable load in ﬁnancial terms as well
as in terms of invested time on the end users.
As one of the leading online distributors of 1.5 mil-
lion proteomics products from more than 180 suppliers,
Antibodies-online is committed to provide high quality
reagents for the life sciences. To this endwehave launched the
Independent Validation with our partner Science Exchange to
provide reproducible validation data for selected applications
according to our customer’s requirements.
Since its inception in July 2013 more than 275 validations of
antibodies and ELISA kits have been carried out. In this time
window we have received almost 3000 validation requests
from our customers. This interest illustrates the need for a
program that offers relevant, independent, and standardized
validation data.
http://dx.doi.org/10.1016/j.euprot.2015.07.006
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Sigma–Aldrich has a well-established history in the formu-
lation of analytical standards, including a portfolio of peptide
and protein standards for the development and evaluation of
proteomics workﬂows. We have participated in several inter-
laboratory studies with organizations such as the ABRF and
ProteoRed. Commercialization of associated reference mate-
rials allows the proteomics community to troubleshoot and
optimize sample preparation protocols and performance deﬁ-
ciencies of MS and LC systems. We are interested in further
activities aimed at standardization and QC to improve the
reproducibility of results within and across laboratories.
As a company Sigma–Aldrich is interested in providing
standards and kits which can be used to assess the integrity
of proteins and their PTMs within archived samples (serum,
plasma, and tissue) to ensure their suitability for use in future
analyses. Additionally, we are interested in developing afford-
able solutions for protein sample preservation and sample QC
tests which can be used to ensure the long-term integrity of
samples to be archived within biobanks.
We are also interested in exploring the utility of using
CRISPR knockout technology to validate Ab speciﬁcity. Val-
idating antibody speciﬁcity using knockdown technologies,
such as siRNA and shRNA, can be challenging for proteins
with low expression levels and/or long half-lives. Since CRISPR
technology is highly efﬁcient in creating speciﬁc and perma-
nent genetic knockout mutations, the treated cell population
should have signiﬁcantly more null cells compared to the
mock treated cell population.
Sigma–Aldrich anticipates this will allow more clear mea-
surement of differences between treated and untreated cells.
http://dx.doi.org/10.1016/j.euprot.2015.07.007
